AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

JCR Pharmaceuticals has signed a licence agreement with Alexion, AstraZeneca Rare Disease, for its proprietary JUST-AAV ...

JCR announced that it has entered into a license agreement with Alexion, for JCR’s new, proprietary JUST-AAV capsids to ...

The deal gives AstraZeneca’s rare disease unit Alexion access to specialized capsids developed by the Japanese biotech JCR ...

The company in question is New Haven, Conn.-based Alexion Pharmaceuticals -- best-known for Soliris, a drug that costs insurance companies about $440,000 a year per patient. The reason for the ...

Alexion said it will pay $115 in cash and a portion of its stock for each Synageva share. That puts the total per-share price at about $226, based on the Tuesday closing price of Alexion shares.

A little more than a year since its acquisition by AstraZeneca plc, Alexion Pharmaceuticals Inc. is operating in "the best of both worlds" as the official rare disease unit of the U.K. pharma giant.

Vice Chancellor Morgan T. Zurn for the second time found Alexion liable to Shareholder Representative Services, the Quinn Emanuel Urquhart & Sullivan-represented plaintiff representing former ...

The huge premium drug maker Alexion Pharmaceuticals is paying for Synageva BioPharma—$8.4 billion, or more than double Synageva’s market value—shows how hot the market has become for rare ...

Alexion, AstraZeneca Rare Disease, and DHL Express have teamed up to initiate Ireland's “first” complete transition to sustainable aviation fuel (SAF) for the international air delivery of ...